Skip to main content
Premium Trial:

Request an Annual Quote

Prolor Biotech Takes Option to Peptide Rx Candidates from Weizmann's Yeda R&D

Premium

Israel's Prolor Biotech said recently that it has inked an evaluation and option agreement with Yeda Research and Development, the tech-transfer arm of the Weizmann Institute of Science.

Under the agreement, Prolor, located in the Weizmann Science Park in Nes-Ziona, has the option to obtain from Yeda a license to develop a number of peptide drug candidates, including an anti-obesity peptide, using a delivery technology developed at the Weizmann Institute.

Additional details of the agreement were not disclosed.

"This agreement, enabling us to access novel technology developed by [Weizmann] scientists, represents an exciting opportunity for Prolor," Shai Novik, president of Prolor, said in a statement.

"The first preclinical drug candidate we will evaluate under the agreement is a potential long-lasting anti-obesity compound," Novik added. "We believe the timing is right for us to explore entering this market with a drug candidate that may have strong competitive advantages over other anti-obesity approaches currently in development."

Prolor Biotech, formerly known as Modigene, changed its name in June.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.